MedTrace Logo

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

NCT05055947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-01-25

No results posted yet for this study

Summary

The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.

Conditions

Interventions

DRUG

First line EC/EP+Atezolizumab

Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-07-01
Completion
2021-09-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05055947 on ClinicalTrials.gov